Keratoacanthoma is a common low-grade (unlikely to metastasize or invade) rapidly-growing skin tumour that is believed to originate from the hair follicle and can resemble squamous cell carcinoma.
Keratoacanthoma (KA) 是一种常见的皮肤肿瘤,以快速生长并可能自行消退而著称。它多见于有日晒史、年龄较大、皮肤白皙的男性。虽然手术切除或 Mohs 显微手术是常用的治疗方法,但还有其他多种选择。 Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) 是一种低度恶性肿瘤,起源于皮肤的某些腺体,在显微镜下与 squamous cell carcinoma (SCC) 相似。关于 KA 是否应归类为侵袭性鳞状细胞癌的一个亚型,学界一直存在争议。 Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) 是人类中第二常见的癌症类型,尤其在老年人中更为常见。手术是治疗鳞状细胞癌的主要手段,但对于一些无法手术或选择不手术的患者,可考虑病灶内治疗等其他方案。传统的病灶内治疗(methotrexate 或 5-fluorouracil)已被使用,但对病灶内免疫疗法和溶瘤病毒疗法等新方法的研究仍在进行中。本文将综述 cSCC 的各种病灶内治疗方式,从经典方法到前沿策略。 Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
在显微镜下,角化棘皮瘤 (Keratoacanthoma) 与鳞状细胞癌非常相似。虽然一些病理学家将角化棘皮瘤 (Keratoacanthoma) 归类为一种独特的实体而非恶性肿瘤,但约 6% 的临床和组织学病例会进展为侵袭性鳞状细胞癌。
○ 诊断和治疗
#Dermoscopy
#Skin biopsy